Key Developments: NeoStem Inc (NBS.OQ)

NBS.OQ on NASDAQ Stock Exchange Capital Market

3.39USD
26 Dec 2014
Price Change (% chg)

$0.12 (+3.67%)
Prev Close
$3.27
Open
$3.26
Day's High
$3.42
Day's Low
$3.26
Volume
80,035
Avg. Vol
109,445
52-wk High
$8.29
52-wk Low
$3.10

Search Stocks

Latest Key Developments (Source: Significant Developments)

NeoStem Announces Initial Positive Data from Phase 2 PreSERVE AMI Clinical Trial
Monday, 17 Nov 2014 05:15pm EST 

Neostem Inc:Says initial positive data from its 161 patient Phase 2 PreSERVE AMI (or acute myocardial infarction) clinical trial.Says these data are based on all enrolled patients being treated and having received six month follow-up for imaging and twelve month median length follow up for mortality, adverse events, serious adverse events and major adverse cardiac events.  Full Article

NeoStem Inc secures debt facility
Monday, 29 Sep 2014 07:30am EDT 

NeoStem Inc:Entered into a loan and security agreement with Oxford Finance LLC pursuant to which Oxford has agreed to make a term loan to the company in the principal amount of up to $20 million, and has made the initial disbursement of $15 million.The loan matures in Sept. 2018 and the additional $5 million disbursement is available in the event of the company's consummation of a partnering transaction around the company's NBS10 development program for post acute myocardial infarction (AMI) patients.Oxford will have a security interest in substantially all the company's real and personal property, excluding intellectual property.No warrants or common stock were issued in connection with this financing.WBB Securities, LLC acted as a financial advisor to NeoStem on the transaction.  Full Article

NeoStem Inc announces license agreement with The Rockefeller University
Thursday, 11 Sep 2014 07:30am EDT 

NeoStem Inc:Entered into an exclusive license agreement with The Rockefeller University.Agreement for patented technologies that further expand Company's intellectual property portfolio associated with its Targeted Cancer Immunotherapy Program.  Full Article

NeoStem Inc set to join multiple Russell Indexes
Monday, 23 Jun 2014 07:30am EDT 

NeoStem Inc:Says it is set to join broad-market Russell Global, Russell 3000, and Russell Microcap Indexes when Russell Investments reconstitutes comprehensive set of U.S. and global equity indexes on June 27, 2014.  Full Article

NeoStem announces licensing agreement and plans to begin Phase 2 Hepatocellular Carcinoma Trial in China
Tuesday, 13 May 2014 07:30am EDT 

NeoStem Inc:Signs an exclusive license agreement with Cellular Biomedicine Group (CBMG) to begin a Phase 2 clinical trial in patients with late stage liver cancer.Pursuant to the agreement, cost of Phase 2 trial will be borne by CBMG, and CBMG will also be responsible for all clinical, marketing, and, should a product be approved, commercialization activities in China.Also reaches an agreement with U.S. Food and Drug Administration to begin a Phase 3 clinical trial for lead product candidate, Melapuldencel- T, in metastatic melanoma.Expected to begin in 2014.  Full Article

NeoStem announces closing of acquisition of California Stem Cell, Inc.
Thursday, 8 May 2014 04:11pm EDT 

NeoStem Inc:Closes acquisition of California Stem Cell, Inc.  Full Article

NeoStem Inc's subsidiary enters into a services agreement with IRX Therapeutics Inc
Wednesday, 30 Apr 2014 07:30am EDT 

NeoStem Inc and Progenitor Cell Therapy LLC:Execution of services agreement with IRX Therapeutics Inc.Under which subsidiary will provide services to support IRX's development of IRX-2, primary cell-derived biologic with multiple active cytokine components.IRX-2 is cancer therapeutic designed to activate patient's immune system to broadly restore immunity and overcome cancer-induced immune suppression.  Full Article

NeoStem announces definitive agreement to acquire California Stem Cell, Inc
Monday, 14 Apr 2014 07:00am EDT 

NeoStem Inc:Enters into definitive agreement to acquire California Stem Cell, Inc.Also plans to initiate a pivotal Phase 3 trial of Melapuldencel-T, an autologous melanoma initiating (stem) cell immune based therapy intended to eliminate the tumor cells capable of causing disease recurrence.Definitive merger agreement provides for issuance of an aggregate of up to about 5.33 mln shares of NeoStem common stock.  Full Article

NeoStem Inc begins research collaboration for treatment of skin wounds in Scleroderma
Wednesday, 26 Mar 2014 07:30am EDT 

NeoStem Inc:Signs agreement for research collaboration investigating potential of very small embryonic-like stem cells in treating difficult to heal wounds in animal model of scleroderma.  Full Article

NeoStem Inc's subsidiary announces Bi-Coastal facility expansions
Monday, 10 Mar 2014 07:30am EDT 

NeoStem Inc:Says its subsidiary, Progenitor Cell Therapy has expanded both its Allendale, NJ and Mountain View, CA current Good Manufacturing Practice (cGMP) facilities to significantly increase its engineering and process development laboratories, and controlled environment space available for client needs.PCT's Allendale facility added two clean rooms for a total of five, an increase of 67 pct.  Full Article

Search Stocks